MT-101 IMAGINE Phase 1/2 Study
MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T-cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options that, until now, has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity.
Join our Peripheral T-cell Lymphoma Study
Myeloid has dosed its first patient in the IMAGINE study — a Phase 1/2, multicenter, open-label, dose-escalation, and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL. The dose-escalation portion of this Phase 1 study is currently open and enrolling patients with and without conditioning therapy.
Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.
Access to MT-101 Outside of a Clinical Trial Is Not Currently Available
We recognize the unmet treatment need in patients with T-cell lymphoma who do not qualify for a clinical trial. Myeloid will put into place an expanded access policy once more therapeutic experience is available.